TheraRadar
← Back
Data updated: Jun 28, 2026

NIVAGEN PHARMS INC

Generics

NIVAGEN PHARMS INC is a generic drug manufacturer focused on Oncology.

2020
Since
9
Drugs
-
Trials
0
New Drugs (2yr)

NIVAGEN PHARMS INC's Key Drugs

NIVAGEN PHARMS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NIVAGEN PHARMS INC's Recent FDA Approvals

New NDA/BLA approvals for NIVAGEN PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NIVAGEN PHARMS INC's Therapeutic Areas

NIVAGEN PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
1 drugs

NIVAGEN PHARMS INC's Top Competitors

NIVAGEN PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NIVAGEN PHARMS INC Pipeline Snapshot

Active clinical trials for NIVAGEN PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling